Q2 2024 Amylyx Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Amylyx Pharmaceuticals Inc (AMLX) expanded its late-stage pipeline with the acquisition of Avexitide, a Phase 3 ready asset with FDA breakthrough therapy designation.
- Avexitide has shown significant reductions in hypoglycemic events in clinical trials, with a 66% reduction in level three hypoglycemic events in a Phase 2B trial.
- The company has a strong cash position, with $309.8 million in cash and investments, expected to support operations into 2026.
- Amylyx Pharmaceuticals Inc (AMLX) is on track to initiate a pivotal Phase 3 program for Avexitide in post-bariatric hypoglycemia (PBH) in Q1 of next year.
- The company is actively engaging with the FDA and planning for a single Phase 3 clinical trial for AMX0035 in Wolfram syndrome, with promising data on glycemic control and other outcomes.
- Net product revenue was negative $1 million for the second quarter due to adjustments to gross to net revenue reserve estimates.
- The company recorded a net loss of $72.7 million for the second quarter, including restructuring charges.
- Cost of sales increased to $7.4 million for Q2, primarily related to estimated losses on firm commitments under commercial manufacturing and supply agreements.
- Research and development expenses were $23.3 million for the quarter, reflecting a decrease due to restructuring and the outcome of the Phoenix trial.
- Selling, general, and administrative expenses were $21.6 million for Q2, a decrease from the previous year, primarily due to a decline in payroll and personnel-related costs.
Good morning. My name is Camille, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals' Second Quarter 2024 Earnings Conference Call. All participants will be on a listen-only mode. After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Lindsey Allen, Head Investor Relations and Communications. Please proceed.
Good morning and thank you all for joining us today to discuss our second quarter 2024 financial results. With me on the call today are Joshua Cohen and Justin Klee, our co-CEOs, Dr. Camille Bedrosian, our Chief Medical Officer, and James Frates, our Chief Financial Officer.
Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
